Drugmakers have sharply boosted prices of some older, low-cost prescription medicines amid supply shortages and recalls—in some cases, by threefold and more.
About coaadminThis author has not yet filled in any details.
So far coaadmin has created 2986 blog entries.
The Medicare Payment Advisory Commission on Thursday recommended that Congress pass legislation to consolidate most of Medicare's value-based quality programs and boost payments for high-performing hospitals.
The Institute for Clinical and Economic Review is working on a new annual report that will call out specific drugs with big price increases that are “unsupported” by independent medical evidence, Axios’ Bob Herman: reports.
Lisa Crook was lucky. She saved $800 last year after her insurance company started covering a new, less expensive insulin called Basaglar that was virtually identical to the brand she had used for years.
Earlier this week, the National Osteoporosis Foundation wrote members of Congress on behalf of more than 200 organizations to express concern over efforts that would allow Medicare to negotiate prices for the Part D drug program.
A coalition of patient advocacy and medical groups — led by the American Cancer Society’s advocacy arm and joined by the American Medical Association — launched an advertising campaign Thursday to drum up opposition to a proposed change to Medicare they say will “put patients’ lives at risk.”
Senate Finance Republicans met with Health and Human Services Secretary Alex Azar on Wednesday to discuss the administration's drug pricing proposals.
Pharmacy-benefits managers, the powerful middlemen who help select which drugs are covered for patients and negotiate discounts with drugmakers, could soon get more scrutiny in Indiana.
It is a "medically sound" idea to empower physicians to safely recycle highly expensive oral chemotherapies and thereby increase access and minimize waste, write a group of oncologists in a commentary published online December 19 in the Oncologist.
A key Democrat on drug pricing issues said Wednesday that she does not want to “punish” the pharmaceutical industry, striking a softer tone than many other Democrats do on the issue.